Evidence map›Paper›PMID 41982677›Full record

ArticleComputational and structural biotechnology journal2026

CancerSubtypeXplore: A Modular Platform for Multiomics Cancer Subtype Prediction and Biomarker Consensus Discovery.

Dingnan Jin, Bian Bian, Yutaka Saito

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dingnan JinDepartment of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba 277-0882, Japan.
Bian BianDepartment of Data Science, School of Frontier Engineering, Kitasato University, Sagamihara, Kanagawa 252-0373, Japan.
Yutaka SaitoDepartment of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba 277-0882, Japan.ORCID https://orcid.org/0000-0002-4853-0153

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying reproducible biomarkers and cancer subtypes from large-scale multiomics data remains a challenging task, as current computational frameworks often require coding expertise and lack standardized datasets for model benchmarking and exploration. To address these limitations, we developed CancerSubtypeXplore, a modular and user-friendly platform for multiomics cancer subtype prediction and biomarker discovery. The system integrates 4 main components: (a) a dataset module providing standardized and curated multiomics datasets from 17 The Cancer Genome Atlas cancer types, including mRNA, DNA methylation, and microRNA profiles; (b) a machine learning module for automated benchmarking using classical algorithms such as support vector machines and random forests; (c) design your deep learning model module that allows users to design and train customized neural network architectures without coding; and (d) a biomarker analysis module that extracts prediction-contributed features as biomarkers from each trained model, computes their intersections, and ranks them by frequency to identify robust cross-model or cross-cancer biomarkers. Benchmark experiments demonstrate consistent subtype prediction accuracy across multiple cancer types and reveal overlapping biomarkers that may serve as potential pan-cancer signatures. CancerSubtypeXplore provides a transparent, reproducible, and extensible environment for biomedical researchers to explore multiomics datasets, evaluate diverse models, and identify robust biomarkers.

Identifiers

PMID41982677
PMCPMC13072625

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.